Announced details
Industry-academia collaboration, new research and development, pharmaceutical research and development for rare diseases, the acute phase of spinal cord injury, vocal cord scarring
The event's speakers, participating companies and organiser. No capital, personnel or business relationships are described.
ACTjapan is a Japan translational research alliance involving 35 research institutions nationwide, centred on Osaka University. MARC is a metropolitan-area AR consortium comprising clinical research institutions, mainly private universities in the Tokyo metropolitan area, including Keio University. No detailed overview is provided for LINK-J or the Japan Biotech Council.
Nihonbashi Life Science Hub
In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.
| Item | Details |
|---|---|
| Names of Products / Services Covered | oremepermin alfa (オレメペルミン アルファ) |
| Counterparty | ACTjapan, MARC, LINK-J, Japan Biotech Council |
| Counterparty overview | ACTjapan is a Japan translational research alliance involving 35 research institutions nationwide, centred on Osaka University. MARC is a metropolitan-area AR consortium comprising clinical research institutions, mainly private universities in the Tokyo metropolitan area, including Keio University. No detailed overview is provided for LINK-J or the Japan Biotech Council. |
| Relationship with the Company | The event's speakers, participating companies and organiser. No capital, personnel or business relationships are described. |
| Launch date | 27 November 2026 (scheduled; event date) |
| Applicable area | Industry-academia collaboration, new research and development, pharmaceutical research and development for rare diseases, the acute phase of spinal cord injury, vocal cord scarring |
| Location | Nihonbashi Life Science Hub |
Items this document does not state (11)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To introduce the company's business and research and development activities through participation in an event that connects companies' research and development needs with research results and technology seeds from universities and research institutions, thereby creating opportunities for industry-academia collaboration and new research and development, and to foster interaction and collaboration with academia and related companies.